ACCELERON PHARMA INC - COMMON STOCK (XLRN) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2014 to Q3 2025

Type / Class: Equity / COMMON STOCK
Symbol: XLRN
Price per share: $179.00
All holders as of 30 Sep 2025: Q3 2025
Total 13F shares: 2
Total reported value: $358
Share change: 0
Number of holders: 1

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

As of 30 Sep 2025, 1 institutional investors reported holding 2 shares of ACCELERON PHARMA INC - COMMON STOCK (XLRN).

Institutional Holders of ACCELERON PHARMA INC - COMMON STOCK (XLRN) across Reporting Periods

Period	Reported Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price (Median)	Investors
2025 Q3	2	$358				$179.00	1
2025 Q2	2	$358				$179.00	1
2025 Q1	2	$358				$179.00	1
2024 Q4	2	$358				$179.00	1
2024 Q3	2	$358				$179.00	1
2024 Q2	2	$358				$179.00	1
2024 Q1	2	$358				$179.00	1
2023 Q4	2	$358				$179.00	1
2023 Q3	2	$358				$179.00	1
2023 Q2	2	$358				$179.00	1
2023 Q1	2	$358				$179.00	1
2022 Q4	2	$358	+$358			$179.00	1
2021 Q4	0	$0	-$9,188,239,428	$0	$0	$179.00	0
2021 Q3	53,532,419	$9,213,602,999	+$88,352,146	$193,785,000	$472,674,000	$172.10	321
2021 Q2	54,009,713	$6,777,439,742	+$6,771,060	$43,367,900	$24,799,000	$125.49	267
2021 Q1	53,915,109	$7,304,660,689	+$50,812,289	$40,555,100	$32,275,000	$135.61	251
2020 Q4	54,120,723	$6,923,891,307	-$150,205,442	$22,566,000	$18,922,000	$127.94	250
2020 Q3	54,061,080	$6,083,968,433	+$673,763,565	$14,060,000	$18,108,000	$112.53	235
2020 Q2	48,204,313	$4,593,364,866	+$46,875,634	$42,272,000	$49,461,000	$95.27	233
2020 Q1	47,736,075	$4,287,457,211	+$79,945,031	$55,945,000	$49,357,000	$89.87	215
2019 Q4	48,338,495	$2,562,906,827	+$19,665,179	$9,420,000	$15,303,000	$53.02	178
2019 Q3	48,001,349	$1,896,958,223	-$366,122	$7,651,000	$3,928,000	$39.51	170
2019 Q2	48,003,054	$1,971,835,206	-$47,514,370	$4,232,000	$4,425,000	$41.08	164
2019 Q1	49,247,216	$2,295,462,322	+$223,990,335	$12,020,000	$12,509,000	$46.57	169
2018 Q4	44,529,426	$1,939,376,023	-$30,688,010	$1,760,000	$12,807,000	$43.55	158
2018 Q3	44,756,087	$2,560,244,057	+$215,127,359	$7,338,000	$36,843,000	$57.23	163
2018 Q2	40,934,972	$1,986,141,245	+$28,088,503	$61,896,000	$24,900,000	$48.52	166
2018 Q1	40,736,075	$1,592,413,587	+$27,611,475	$8,138,000	$2,381,000	$39.10	148
2017 Q4	40,091,492	$1,701,411,015	-$5,525,047	$4,168,000	$4,440,000	$42.44	136
2017 Q3	39,447,711	$1,472,568,648	+$186,509,070	$11,062,000	$2,414,000	$37.32	148
2017 Q2	34,569,756	$1,047,261,933	+$61,565,489	$6,992,000	$1,493,000	$30.39	126
2017 Q1	32,621,602	$863,474,327	+$97,263,259	$2,211,000	$819,000	$26.47	135
2016 Q4	32,362,647	$825,902,832	+$18,356,861	$1,908,000	$579,000	$25.52	142
2016 Q3	32,773,554	$1,185,318,197	+$99,254,466	$2,666,000	$2,118,000	$36.19	136
2016 Q2	30,062,198	$1,021,711,616	+$31,977,311	$4,258,000	$663,000	$33.98	132
2016 Q1	29,268,235	$772,223,004	+$111,812,556	$6,656,000	$1,824,000	$26.39	123
2015 Q4	24,914,233	$1,213,678,817	+$61,212,311	$18,251,000	$8,991,000	$48.76	122
2015 Q3	24,288,268	$604,759,469	-$12,559,822	$4,032,000	$1,627,000	$24.90	109
2015 Q2	24,734,069	$782,396,217	-$21,689,983	$4,835,000	$2,547,000	$31.64	116
2015 Q1	25,083,528	$954,777,613	+$15,239,658	$5,584,000	$5,665,000	$38.06	114
2014 Q4	24,796,115	$966,117,002	+$125,873,005	$5,353,000	$10,297,000	$38.96	110
2014 Q3	21,141,565	$639,314,054	+$5,549,665	$1,732,000	$1,823,000	$30.24	83
2014 Q2	20,868,859	$708,920,517	+$122,086,996	$245,000	$2,956,000	$33.97	91
2014 Q1	17,286,706	$595,999,178	+$134,232,969			$34.50	78